Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

The latest announcement is out from Savara ( (SVRA)). In January 2026, Savara updated its corporate presentation to provide an expanded overview of autoimmune pulmonary alveolar proteinosis ...

--Savara Submitted the MOLBREEVI Biologics License Application (BLA) in December 2025 for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)-- LANGHORNE, Pa., ...

Savara Inc. (NASDAQ: SVRA) began the trading day with its shares slightly in the green. The company, a clinical stage biopharmaceutical firm focused on rare respiratory diseases, today announced the ...

About Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of ...

LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has issued inducement equity awards to two newly hired employees, a move ...

PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026, ...

Hwa Chong Institution (HCI) refutes a claim that it punished students for discussing canteen food quality with the media after images of the meals circulated online. A Reddit post claimed nine ...